Gonorrhea symptoms usually appear within about two weeks of exposure, when they appear at all. In people with a penis, burning urination and discharge often show up within days. Many infections, especially in the throat and in women, cause no symptoms ever, so timing a test matters more than waiting for signs.
test all exposed sites
500 mg IM, single shot
| Item | Value |
|---|---|
| Test method | NAAT — test all exposed sites |
| Treatment | ceftriaxone — 500 mg IM, single shot |
| Throat infection | harder to cure |
| Retest | 3 mo |
The essentials: incubation versus the test window
Gonorrhea is caused by the bacterium Neisseria gonorrhoeae, which can infect the genitals, rectum, and throat CDC. After the bacteria reach a mucous surface, they need time to multiply enough to either trigger inflammation you can feel or to be detectable by a test. The symptom clock and the test clock don't run together, and confusing them is the most common reason people test too early or wait too long.
Symptoms, when they happen, tend to surface within a couple of weeks. But a large share of gonorrhea infections never produce a single symptom. In women, urogenital infection is commonly asymptomatic, and the majority of throat infections are silent in everyone. The CDC gives no single percentage for how often this happens, only that it's frequent. A throat infection can quietly persist for up to sixteen weeks, so you can pass it on long after a one-time exposure with no clue anything is wrong.
Don't use the absence of symptoms as proof you're clear. If you've had a known or possible exposure, the question is when a test becomes reliable, not whether you feel anything. For that timing, see our guide on when to test after exposure.
What gonorrhea symptoms feel like and when they show up
Symptoms reflect inflammation at whichever site the bacteria landed, so they differ by anatomy. Below is what to watch for and roughly when.
Symptoms in men
Men are more likely than women to notice something, and usually sooner. The classic triad is burning when urinating; a white, yellow, or green discharge from the penis; and, less commonly, swollen or painful testicles. The discharge comes from inflammation of the urethra, where the bacteria irritate the lining and the body floods it with pus-forming white cells. A swollen, painful testicle can mean epididymitis (inflammation of the coiled tube behind the testicle that stores sperm), which can threaten fertility if ignored, so get seen promptly rather than waiting.
Symptoms in women
Most women have no symptoms at all. When symptoms do appear they're easy to mistake for a bladder infection or a yeast problem: painful or burning urination, increased vaginal discharge, or bleeding between periods. The signs are subtle and inconsistent, so screening matters far more here than symptom-watching. We cover the full picture, including the risk of untreated spread to the reproductive organs, in gonorrhea symptoms in women.
Rectal and throat infections
Rectal infection from receptive anal sex can cause discharge, anal itching, soreness, bleeding, or painful bowel movements, though it's often silent too. Throat (pharyngeal) infection from oral sex is the quietest and the hardest to clear, partly because the pharynx is where gonorrhea can pick up resistance genes from harmless throat bacteria. A sore throat is rarely the tip-off, and most people never know they carry it.
Testing: when it's accurate and what to expect
The preferred test is a NAAT (nucleic acid amplification test), which finds bacterial genetic material directly. It's highly accurate, with sensitivity usually above 90% and specificity around 99% CDC STI guidelines. Because it detects the organism directly, it can turn positive before any symptom would. Testing too soon after exposure still risks a false negative if bacterial levels haven't built up, so the timing in when to test after exposure applies.
In practice, a visit is quick. You give a first-catch urine sample (the first part of the stream, not midstream), and if you've had oral or anal sex you add a quick throat or rectal swab. Patient-collected swabs are accepted. Ask for testing at every site you've been exposed at, because a urine test alone will miss a throat or rectal infection entirely, and those are the ones most likely to be silent. You can get tested at a clinic, and public clinics often provide it free or low-cost.
Treatment: a single shot, not take-home pills
Gonorrhea is curable, though medicine cannot reverse damage already done. First-line treatment is a single intramuscular injection of ceftriaxone (500 mg for people under 150 kg, or 1 g for those 150 kg or more), which covers genital, rectal, and throat infections MMWR 2020. If chlamydia hasn't been ruled out, a short course of oral doxycycline is added.
The 2020 guidelines dropped the older two-drug approach. Azithromycin was removed because resistance climbed fast, with isolates showing elevated azithromycin levels rising more than sevenfold over a few years, so ceftriaxone now stands alone at a higher dose than before. You'll get the injection in the clinic rather than a bottle of pills to take home, because oral antibiotics are no longer reliable enough to be first-line.
New oral options for resistant cases
Two oral drugs were FDA-approved in December 2025 for uncomplicated urogenital gonorrhea: zoliflodacin (Nuzolvence), a single oral dose FDA, 2025, and gepotidacin (Blujepa), oral tablets reserved for when few other options exist due to resistance FDA, 2025. They're the first new antibiotic classes for gonorrhea in over thirty years and work through novel mechanisms, but neither replaces ceftriaxone as first-line yet. Both are held in reserve for resistance scenarios to preserve their effectiveness.
Why the throat is the hard case
Throat infections are harder to cure than genital or rectal ones. Even fully susceptible pharyngeal infections fail ceftriaxone a small but real fraction of the time, so a test-of-cure is advised for the throat, returning a week or two after treatment. If cefixime (an oral backup) is used because ceftriaxone isn't available, remember it treats only urogenital and rectal infection and does not reliably clear the throat.
| Site | Typical symptom timing | Often silent? | Test-of-cure needed? |
|---|---|---|---|
| Penis (urethra) | Often within days | Less often | No (routine retest at 3 months) |
| Vagina/cervix | Within ~2 weeks if at all | Commonly | No (routine retest at 3 months) |
| Rectum | Variable; often silent | Often | No |
| Throat | Rarely noticeable | Majority silent | Yes (return 7–14 days after treatment) |
After treatment, two follow-up steps matter. Abstain from sex for seven days after the injection so you don't reinfect a partner or get reinfected. And plan to retest in about three months, since reinfection is common and a fresh exposure doesn't announce itself any louder than the first one did.
Prevention that actually works
Consistent, correct condom use every time lowers risk; mutual monogamy with a tested partner and regular screening of every exposed site round it out. Notify and treat partners from the prior sixty days, and where in-person care isn't possible for a heterosexual partner, expedited partner therapy (sending treatment to the partner) may be an option where it's legal. The full playbook is in how to prevent gonorrhea.
DoxyPEP—a dose of doxycycline taken after sex—cuts chlamydia and syphilis substantially but is much less effective for gonorrhea and gives inconsistent results CDC DoxyPEP guidance. The CDC does not recommend it specifically for gonorrhea prevention, partly out of concern it could drive tetracycline resistance in N. gonorrhoeae.
When to see a clinician
See a clinician promptly if you have burning urination, unusual genital, rectal, or throat discharge, bleeding between periods, or a swollen, painful testicle. Also get checked if a partner tests positive or if you've had a new or anonymous partner, even with no symptoms. Reported gonorrhea has actually been falling, with about 601,000 cases in 2023, but rates vary enormously by place, so local risk matters CDC AtlasPlus, 2023. Ceftriaxone-resistant strains exist internationally, which makes prompt, complete treatment and follow-up testing more important than ever WHO.